VIIV-205712

Study Sponsor: ViiV

Study Title

Phase I, single-center, open label, fixed-sequence cross-over study to evaluate the effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects

Medicine or Vaccine (generic name)

cabotegravir

Sponsor Identification Number

205712

Trial Registry Identification Number(#'s)

NCT03149848 2017-000103-25

Medical Condition

Infection, Human Immunodeficiency Virus

Phase

Phase 1

Link to study details on the ViiV Clinical Study Register

https://www.viiv-studyregister.com/en/study/?id=205712

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT03149848

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-000103-25

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

The data for this study is available in CDISC format.

Date Added to this Site

May 2020